News

September 3, 2024

Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect – FiercePharma

Scilex’s Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect FiercePharma
Source: Scilex’s Semnur Pharmaceuticals to go public through .5B SPAC merger as it advances sciatica prospect – FiercePharma

By sf-admin